Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
Hamza Mohamed/LinkedIn
Jul 6, 2026, 19:20

Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE

Hamza Mohamed, Medical Director and Medical Resident St. Paulos MMH at Ethiopian Health professionals’ Associations, shared a post on LinkedIn:

“Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute Pulmonary Embolism (PE)

The 2026 AHA/ACC guideline represents the first comprehensive U.S. clinical practice guideline dedicated entirely to the evaluation and management of acute pulmonary embolism. It introduces several important practice-changing recommendations.

1. A new PE classification replaces ‘massive’ and ‘submassive’

The guideline introduces AHA/ACC Acute PE Clinical Categories (A–E), providing a more precise framework based on clinical severity, RV dysfunction, biomarkers, and hemodynamic status to guide management.

2. More patients can be treated as outpatients

  • Category A: Asymptomatic PE – safe ED discharge.
  • Category B: Symptomatic but low-risk PE – early discharge is generally recommended.

This highlights a shift toward individualized, resource-conscious care.

3. PE Response Teams (PERTs) receive a Class I recommendation

Multidisciplinary PE teams are now strongly recommended to facilitate rapid risk stratification and timely treatment decisions.

4. Anticoagulation updates

  • LMWH is preferred over UFH when initial parenteral anticoagulation is needed (unless specific indications for UFH exist).
  • DOACs are preferred over warfarin in eligible patients because they reduce recurrent VTE and major bleeding.

5. Advanced reperfusion therapies

Systemic thrombolysis, catheter-directed therapies, mechanical thrombectomy, and surgical embolectomy should be selected according to the new A–E risk categories, with the strongest role in patients with hemodynamic compromise.

6. Extended anticoagulation

Patients with a first unprovoked PE or persistent risk factors should generally continue anticoagulation beyond the initial 3–6 months, after balancing bleeding risk.

7. Long-term follow-up is now emphasized

Patients should be assessed for persistent dyspnea and functional limitation for at least 12 months to detect chronic thromboembolic pulmonary disease (CTEPD) or other post-PE complications.

Take-home message:

The 2026 guideline moves PE management toward precision medicine—replacing outdated terminology, expanding outpatient management for low-risk patients, prioritizing multidisciplinary care, and strengthening long-term follow-up.”

Hamza Mohamed

Stay updated with Hemostasis Today.

2026 AHA/ACC Multisociety Guideline Acute Pulmonary Embolism Anticoagulation Blood Cardiology catheter-directed therapies Chronic Thromboembolic Pulmonary Disease CTEPD DOACs Dyspnea Hamza Mohamed Health Hematology Hemostasis News Hemostasis Today LMWH Mechanical thrombectomy Medicine PE PE Response Teams PERTs Pulmonary embolism Surgical embolectomy Thrombolysis U.S. UFH VTE Warfarin
NewsFeed